| 1. |
Zaenglein A, Thiboutot D. Acne Vulgaris. In: Bolognia J, Jorizzo J, editors. Dermatology. 3 th ed. International. [Philadelphia]: Elsevier; 2012. p. 545-58.
|
| 2. |
James W, Berger TG. Andrews Diseases of the Skin Clinical Dermatology. 11 th ed. International. [London] Elsevier Saunders; 2011. p. 231.
|
| 3. |
Grove G, Zerweck C, Gwazdauskas J. Tolerability and irritation potential of four topical acne regimens in healthy subjects. J Drugs Dermatol 2013;12:644-9.
|
| 4. |
Habif TP, Campbell JR, compbell Jl, chapman MS, Dinulos J. Skin Disease. 3 th ed. UK/USA: Eisevier; 2011. p. 104-5.
|
| 5. |
Burns T, Breathnach S. Rook's Text book of Dermatology. 8 th ed. UK/USA: Wiley-Blackwell; 2010. p. 41-2.
|
| 6. |
Tan HH. Topical antibacterial treatments for acne vulgaris: Comparative review and guide to selection. Am J Clin Dermatol 2004;5:79-84.
|
| 7. |
Schafer F, Fich F, Lam M, Gárate C, Wozniak A, Garcia P. Antimicrobial susceptibility and genetic characteristics of Propionibacterium acnes isolated from patients with acne. Int J Dermatol 2013;52:418-25.
|
| 8. |
Brunton LL. Goodman and Gilman's. The Pharmacological Basis of Therapeutics. 12 th ed. International. New York: Mc Graw Hill Medical; 2011.
|
| 9. |
Abdel Fattah NS, Darwish YW. In vitro antibiotic susceptibility patterns of Propionibacterium acnes isolated from acne patients: An Egyptian university hospital-based study. J Eur Acad Dermatol Venereol 2013;27:1546-51.
|
| 10. |
González R, Welsh O, Ocampo J, Hinojosa-Robles RM, Vera-Cabrera L, Delaney ML, et al. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int J Dermatol 2010;49:1003-7.
|
| 11. |
Nakase K, Nakaminami H, Noguchi N, Nishijima S, Sasatsu M. First report of high levels of clindamycin-resistant Propionibacterium acnes carrying erm (X) in Japanese patients with acne vulgaris. J Dermatol 2012;39:794-6.  [ PUBMED]
|
| 12. |
Trevor A, Katzung BG, Hall MK, Masters SB. Pharmacology Katzung and Trevor's. 10 th ed. International Edition. New York: Mc Graw Hill Medical; 2013. p. 391-395.
|
| 13. |
Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Drugs 2013;73:779-87.
|
| 14. |
Pochi PE, Shalita AR, Strauss JS, Webster SE. report of the consensus conference on acne classification. J Am acad dermatol 1991;24:495-500.
|
| 15. |
Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol 2009;75:323-6.  [ PUBMED]
|
| 16. |
Sandoval LF, Hartel JK, Feldman SR. Current and future evidence-based acne treatment: A review. Expert Opin Pharmacother 2014;15:173-92.
|
| 17. |
Antonio JR, Pegas JR, Cestari TF, Do Nascimento LV. Azithromycin pulses in the treatment of inflammatory and pustular acne: Efficacy, tolerability and safety. J Dermatolog Treat 2008;19:210-5.
|
| 18. |
Maleszka R, Turek-Urasinska K, Oremus M, Vukovic J, Barsic B. Pulsed azithromycin treatment is as effective and safe as 2-week-longer daily doxycycline treatment of acne vulgaris: A randomized, double-blind, noninferiority study. Skinmed 2011;9:86-94.
|
| 19. |
Hasibur MR, Meraj Z. Combination of low-dose isotretinoin and pulsed oral azithromycin for maximizing efficacy of acne treatment. Mymensingh Med J 2013;22:42-8.
|
| 20. |
McHugh RC, Rice A, Sangha ND, McCarty MA, Utterback R, Rohrback JM, et al. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. J Dermatolog Treat 2004;15:295-302.
|
| 21. |
Shirazpour M, Firooz A, Pazooki H, Resaei S. Comparison of topical azithromycin and clindamycin in the treatment of mild to moderate acne vulgaris. Iran J Dermatol 2008;11:67-72.
|
| 22. |
Hajiheydari Z, Mahmoudi M, Vahidshahi K, Nozari A. Comparison of efficacy of azithromycin vs. clindamaycin and erythromycin in the treatment of mild to moderate acne vulgaris. Pak J med sci 2011;27:68-72.
|
| 23. |
Labro MT. Anti-inflammatory activity of macrolides: A new therapeutic potential? J Antimicrob Chemother 1998;41 Suppl B: 37-46.
|